1-2 of 2
Anu Räsänen, MD
Close
Sort by
Journal Articles

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Bengt Simonsson, MD, Tobias Gedde-Dahl, MD, Berit Markevärn, MD, Kari Remes, MD, Jesper Stentoft, MD, Anders Almqvist, MD, Mats Björeman, MD, Max Flogegård, MD, Heikki Hallman, MD, Perttu Koskenvesa, MD, Anders Lindblom, MD, Claes Malm, MD, Satu Mustjoki, MD, Kristina Myhr-Eriksson, MD, Anu Räsänen, MD, Marjatta Sinisalo, MD, Risto Sippola, MD, Anders Själander, MD, Ulla Strömberg, MD, Ole Weiss Bjerrum, MD, Hans Ehrencrona, MD, Franz Gruber, MD, Veli Kairisto, MD, Karin RN Olsson, Arnon Nagler, MD, Johan Lanng Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo Porkka, MD, for the Nordic CML Study Group (NCMLSG)
Journal: Blood
Blood (2009) 114 (22): 3280.
https://doi.org/10.1182/blood.V114.22.3280.3280
Published: 2009
Journal Articles

Imatinib Discontinuation Following a Major Molecular Response: Impact of Interferon Alpha and Leukemia Stem Cell Burden (The STOP Study).

Perttu Koskenvesa, MD, Satu Mustjoki, MD, PhD, Anu Räsänen, MD, Mirja Vapaatalo, MD, Kari Remes, MD, PhD, Tuija Lundán, MSc, PhD, Jukka Vakkila, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2121.
https://doi.org/10.1182/blood.V112.11.2121.2121
Published: 2008